TABLE 3.
Pretransplant cPRA, HLA antibody, and DSA
| Subject | Baseline maximum cPRA |
Anti-HLA Ab |
Renal DSA |
Islet DSA |
|---|---|---|---|---|
| 1a | 7 | Yes | No | No |
| 2 | 0 | No | No | No |
| 6 | 0 | No | No | No |
| 7 | 0 | No | No | No |
| 8b | 0 | Weak | No | Weak |
| 10 | 0 | No | No | No |
| 12 | 0 | No | No | No |
| 20 | 0 | No | No | No |
| 22 | 96 | Yes | Yes | Yes |
| 23c | 0 | No | Weak | No |
| 24 | 0 | No | No | No |
a
Weak HLA class I reactivity (A23-2100 MFI).
b
Weak donor specific antibody (DSA) to islet HLA class II specificity (DQ7; mean fluorescence intensity (MFI) in the range of 700-960) was present pretransplant which was below the predetermined threshold for positivity.
c
Weak DSA to kidney HLA class II specificity (DQ7,8,9; MFI 500-1300) which was below the predetermined threshold for positivity.